WIRED reported on October 21, 2026, that the OpenAI Startup Fund and Founders Fund are backing Coherence Neuro in a $45 million financing. Coherence is developing a brain implant intended to detect and potentially treat cancer. The $45 million is the reported round total, not a disclosed investment by OpenAI alone.

The round has two different labels

WIRED described the financing as a seed round. Coherence Neuro cofounder Ben Woodington called it a Series A and said Founders Fund and The OpenAI Startup Fund co-led it. Both accounts give the same total, but neither specifies how much any investor contributed.

Woodington also named Lux Capital, 8VC, Timeless, SV Angel, Ahren Innovation Capital, and Olive Capital as new investors. He said earlier backers Blackbird, Possible Ventures, Topology Ventures, Artesian, XEIA Venture Partners, Xtal, and Divergent doubled down.

What the human testing has involved

In summer 2026, Coherence briefly tested the implant’s recording capability in three people undergoing brain-tumor surgery at Royal Melbourne Hospital, WIRED reported. The implant remained in place for roughly 30 minutes before removal. WIRED described the procedure as an initial safety check; it did not evaluate whether the device could accurately detect or treat cancer.

WIRED separately reported that Coherence was testing recording and stimulation in an additional seven patients. The company’s longer-term plan is a human trial targeting glioblastoma. These are distinct stages of research, and the reported brief recording test was not a treatment outcome.

Coherence says its AI models can identify electrical signals associated with brain tumors in animals and distinguish signals linked to tumors growing, shrinking, or recurring. The implant is designed to record neural signals and deliver mild electrical stimulation, with the aim of developing a cancer treatment that can respond to those signals.

The company’s stated research plans

Woodington said the financing would support the planned long-term glioblastoma trial and a preclinical research pipeline across pancreatic cancer and beyond. Coherence’s proposed approach remains under development.

Woodington also said OpenAI would not have access to brain or other health data generated by Coherence.